Tech Company Financing Transactions
Phosplatin Therapeutics Funding Round
Private investors invested in a $18.4 million funding round for Phosplatin Therapeutics. The financing round was announced on 8/31/2020.
Transaction Overview
Company Name
Announced On
8/31/2020
Transaction Type
Venture Equity
Amount
$18,400,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance PT-112 through clinical development as a monotherapy, including in mCRPC and multiple myeloma, and in combination with PD-L1 immune checkpoint inhibition.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1350 Ave. of the Americas 23rd Floor
New York, NY 10019
USA
New York, NY 10019
USA
Phone
Website
Email Address
Overview
Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia. It holds the exclusive, global license to phosphaplatins, a family of novel agents currently in clinical development for the treatment of both solid tumors and hematological cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Fallon
Chief Medical Officer
Joseph O'Donnell
Chief Operating Officer
Matthew Price
Vice President
Brooke Raphael
Vice President
Jason Summa
VP - Finance
Frances Bonham
VP - R & D
Tyler Ames
Browse more venture capital transactions:
Prev: 8/26/2020: Socure venture capital transaction
Next: 8/31/2020: Reliable Robotics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs